Allergic skin disease is among the most common and welfare-impactful conditions in dogs, causing chronic itch, recurrent infections, and significantly diminished quality of life. Modern treatment options have transformed welfare outcomes.
Chronic allergic itch represents a persistent welfare burden that is often underestimated by owners who see 'just scratching.' The itch-scratch cycle in atopic dogs causes sleep disruption, social withdrawal, and behavioral changes that affect the entire quality of life. Secondary infections - painful, malodorous, and recurring - add to the suffering. Dogs that scratch ears chronically develop painful otitis externa; those that lick feet develop interdigital pyoderma. Before modern targeted therapies, treatment options required significant side-effect trade-offs. The advent of oclacitinib and lokivetmab represents a genuine welfare advance - highly effective itch control with improved safety profiles that have transformed quality of life for millions of allergic dogs.